Вы находитесь на странице: 1из 16

Am J Physiol Heart Circ Physiol 310: H137–H152, 2016. First published October 16, 2015; doi:10.1152/ajpheart.00618.2015.


Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute?

Mark C. Chappell

The Hypertension and Vascular Research Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina

Submitted 6 August 2015; accepted in final form 15 October 2015

Chappell MC. Biochemical evaluation of the renin-angiotensin system: the good, bad, and absolute? Am J Physiol Heart Circ Physiol 310: H137–H152, 2016. First published October 16, 2015; doi:10.1152/ajpheart.00618.2015.—The renin- angiotensin system (RAS) constitutes a key hormonal system in the physiological regulation of blood pressure through peripheral and central mechanisms. Indeed, dysregulation of the RAS is considered a major factor in the development of cardiovascular pathologies, and pharmacological blockade of this system by the inhibition of angiotensin-converting enzyme (ACE) or antagonism of the angio- tensin type 1 receptor (AT 1 R) offers an effective therapeutic regimen. The RAS is now defined as a system composed of different angiotensin peptides with diverse biological actions mediated by distinct receptor subtypes. The classic RAS com- prises the ACE-ANG II-AT 1 R axis that promotes vasoconstriction; water intake; sodium retention; and increased oxidative stress, fibrosis, cellular growth, and inflammation. In contrast, the nonclassical RAS composed primarily of the ANG II/ANG III-AT 2 R and the ACE2-ANG-(1–7)-AT 7 R pathways generally opposes the actions of a stimulated ANG II-AT 1 R axis. In lieu of the complex and multifunctional aspects of this system, as well as increased concerns on the reproducibility among laboratories, a critical assessment is provided on the current biochemical approaches to characterize and define the various components that ultimately reflect the status of the RAS.

ACE; angiotensin; heart; renin

THE RENIN - ANGIOTENSIN SYSTEM (RAS) comprises a number of

enzymatic pathways and bioactive components that underlie diverse functional actions (Fig. 1). Although originally char- acterized as a circulating endocrine system that targets both peripheral and central receptors, abundant evidence reveals a tissue-based RAS that influences local cellular actions and exhibits intracellular or subcellular components (2, 25, 54, 71, 74, 93, 134, 140, 151). The RAS is classically defined by the activity of angiotensin-converting enzyme (ACE) to form an- giotensin II (ANG II) and the subsequent activation of the angiotensin type 1 receptor (AT 1 R) to mediate both peripheral and central mechanisms in the regulation of blood pressure. The ACE-ANG II-AT 1 R pathway is also associated with var- ious pathologic responses including fibrosis, inflammation, metabolic dysregulation, heart failure, cancer, aging, and dia- betic injury (25, 46, 71, 93, 134). Conversely, alternative RAS pathways may mitigate against the activation of the ACE-ANG II-AT 1 R, particularly in response to the pharmacological blockade of this axis (29, 43, 47, 119). Targeting ACE reduces ANG II expression but enhances the ANG-(1–7)-AT 7 /MasR axis that generally opposes the actions of the ANG II-AT 1 R (29, 43, 44, 103, 119, 120). AT 1 R antagonists may also

Address for reprint requests and other correspondence: M. C. Chappell, Hanes 6042, The Hypertension & Vascular Research Ctr., Wake Forest Univ. School of Medicine, Winston-Salem, NC 27157-1032 (e-mail:


increase the formation of ANG-(1–7) through ACE2, as well as shunt ANG II to the AT 2 R pathway that shares similar prop- erties to the ANG-(1–7) system (12, 25, 29, 44, 47, 119). The RAS is composed of a complex array of components that can be functionally partitioned into distinct receptors, peptides, and peptidases that are downstream from the initial processing of the precursor angiotensinogen to form ANG I by renin (Fig. 1). The review assesses the current biochemical approaches to quantify these components that ultimately define the status of the RAS and to address the consistency of the expected values of the RAS, particularly in lieu of new methodologies applied to the quantification of endogenous angiotensin peptides in various biological compartments including the circulation, tis- sues, urine, and cells.

RAS Protein Components

Angiotensinogen. A soluble glycosylated protein (molecular mass, 50 – 60 kDa), angiotensinogen is the sole precursor of angiotensin peptides and the only known substrate for renin (Fig. 1). Circulating levels of the protein are relatively abun- dant (10 5 g or 10 g/ml; 200 nM), particularly compared with ANG II or ANG-(1–7); therefore, a very small quantity ( 0.1 ml) of serum or plasma is required to quantify angiotensinogen (Table 1). A specific and sensitive enzyme-linked immunoas- say (ELISA) for angiotensinogen developed by Kobori and colleagues (70) is commercially available and comprises anti- bodies directed against two distinct antigenic regions for the


0363-6135/16 Copyright © 2016 the American Physiological Society





Review H138 ASSESSMENT OF THE RAS Fig. 1. Processing cascade for angiotensin peptides. Renin cleaves angio-

Fig. 1. Processing cascade for angiotensin peptides. Renin cleaves angio- tensinogen to angiotensin-(1–10) (ANG I), which is further processed to the biologically active peptides ANG-(1– 8) (ANG II) by angiotensin-converting enzyme (ACE), ANG-(1–7) by endopeptidases such as neprilysin (Nep), and ANG-(1–9) by ACE2. ANG II undergoes further processing by the carboxy- peptidase ACE2 to yield ANG-(1–7) and at the amino terminus by aminopep- tidase A (APA) to form ANG-(2– 8) or ANG III. ANG-(1–7) is metabolized by ACE to form ANG-(1–5), and ANG III is further hydrolyzed by aminopepti- dase N (APN) to yield ANG-(3– 8) or ANG IV. The novel peptides ANG-(1– 12) and ANG-(1–25) may be directly derived from angiotensinogen. ANG II and ANG III recognize the ANG II types 1 and 2 receptors (AT 1 R and AT 2 R, respectively), whereas ANG-(1–9) interacts with the AT 2 R. ANG-(1–7) and Ala 1 -ANG-(1–7) recognize the Mas and Mas-related G protein-coupled recep- tor member D (mRG-D) receptors. ANG IV recognizes the insulin-regulated aminopeptidase (IRAP). DC, aspartic acid decarboxylase. Inset : pathways for ANG-(1–7) formation that may reflect predominantly Nep or ACE2. Adapted from Chappell (29).

capture and detection of angiotensinogen. The angiotensinogen ELISA is quite sensitive (10 11 g or 10 pg; 1.6 amol), exhibits a broad detection range, and is available for multiple species including human, rat, and mouse. There are two angiotensino- gen ELISAs that detect either total (ANG I or des-ANG I) or intact (ANG I) forms of angiotensinogen; therefore, the extent of the renin-processed protein can be determined (IBL-Japan, Gumma, Japan). Importantly, the angiotensinogen ELISAs are not compatible with tissue or cell extracts as opposed to plasma, serum, urine, and cell media, although partial purifi- cation of the tissue or cell extract may potentially remove the

Table 1. Verified angiotensin peptide content

interfering substances. Tissue or cellular content of angio- tensinogen can be quantified by immunoblot, provided a source of the protein is available to standardize this approach, or, alternatively, by addition of renin to quantify ANG I genera- tion from intact angiotensinogen that essentially comprises a “reverse renin assay.” Human urinary levels of angiotensinogen are lower than plasma and average 10 –200 ng/mg creatinine (0.2 to 4 pmol/mg Cr) (Table 1). However, elevated excretion of ang- iotensinogen is considered a biomarker for an activated renal RAS in several models of renal injury that reflects the tubular release of angiotensinogen (5, 69, 72, 113). We applied the total angiotensinogen ELISA and immunoblot methods to assess angiotensinogen expression in the salt-sensitive mRen2.Lewis rat, a congenic model of an activated ACE-ANG II-AT 1 R axis, and observed a marked sex difference in urinary angiotensinogen levels (34) (Fig. 2). Male mRen2.Lewis ex- hibited 200-fold higher excretion of angiotensinogen than females (2 vs. 0.01 pmol/mg Cr) (Fig. 2). Estrogen depletion (ovariectomy) increased angiotensinogen excretion 20-fold, whereas a high-salt (HS) diet enhanced excretion 100-fold compared with intact mRen2 on a normal salt diet. Although both maneuvers increase blood pressure to a similar extent, excretion of angiotensinogen in the HS males remained sixfold higher than the HS females (Fig. 2). Despite the marked increases in excretion, renal mRNA and protein levels of angiotensinogen were not increased following ovariectomy or the HS diet, nor did we detect enhanced release of angio- tensinogen from renal cortical slices in the HS mRen2.Lewis rat (34) (Fig. 2). The elevated urinary angiotensinogen in the mRen2.Lewis likely reflects a greater degree of filtration of the circulating protein rather than a renal source and is perhaps a sensitive biomarker of glomerular damage (34). Renin. Typically regarded as the enzyme that initiates the RAS cascade, renin is an aspartyl-type protease (30 – 40 kDa) that cleaves angiotensinogen to form the inactive peptide ANG I (Fig. 1). The enzyme is synthesized, glycosylated, and re- leased in both inactive (prorenin) and active forms by the juxtaglomerular cells of the renal cortex at a higher prorenin- to-renin ratio. A second source of renal renin is the collecting duct cells that secrete active renin into the tubular fluid (52, 71, 82, 92, 113). There is evidence for alternative gene products of intracellular renin in the kidney, brain, and adrenal that may



ANG-(1–8) (ANG II) ANG-(2–8) (ANG III) ANG-(1–9) ANG-(1–10) (ANG I) *Angiotensinogen (Aogen)

Plasma, fmol/ml (22, 24, 30, 37, 78, 97–100, 102, 125) Adrenal, fmol/g (22, 24, 30, 37, 128) Kidney, fmol/g (22, 24, 37, 70, 101, 128,

5–80 (5–80 pM)


5–50 (5–50 pM)


1–10 (1–10 pM)


1 (1 pM) 10–135 (10–135 pM) 50,000–200,00 (50–200 nM) —









Lung, fmol/g (22, 70) Liver, fmol/g (70) Heart, fmol/g (22, 37, 85, 94, 95, 101, 128) Ovary, fmol/g (37) Uterus, fmol/g (37) Adipose, fmol/g (22, 23) Brain, fmol/g (22, 37, 127) Urine, pmol/mg creatinine (34, 45, 50, 70, 115, 132) Cells, fmol/mg (9, 38, 77, 132, 141)































Peptide values derived from radioimmunoassay (RIA)-HPLC or HPLC-mass spectrometry corrected by molecular size. Values from direct RIA or ELISA. Tissue levels are fmol/g wet weight. Cell content is fmol/mg protein.

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org





  Review ASSESSMENT OF THE RAS H139 Fig. 2. Influence of a high-salt (HS) diet and

Fig. 2. Influence of a high-salt (HS) diet and ovariectomy (OVX) on angiotensinogen ex- cretion in the mRen2.Lewis rats. A : angio- tensinogen excretion in female and male mRen2.Lewis under normal salt (NS, 0.5% Na) and HS (5% Na) diets for 10 wk (5 to 15 wk of age) and in ovariectomized (OVX) females (at 5 wk of age). The mean values for angiotensinogen excretion are given above each bar. B : angiotensinogen mRNA levels and protein expression in intact and OVX females (left ) and males ( right ) on NS or HS diets. C : urinary excretion of ANG II

( top ) and ANG-(1–7) (bottom ) in intact or

OVX females and males on NS and HS diets. Urinary levels of angiotensinogen were mea- sured by a total angiotensinogen ELISA and angiotensin peptides by direct radioimmuno- assays (RIAs); all values were normalized to urinary creatinine [mg creatinine (Cr)]. Rel- ative angiotensinogen mRNA levels were assessed by real-time PCR and protein ex- pression by immunoblot that was normalized to elongation factor 1- (EF1- ). AGT, angiotensinogen; OD, optical density. *P 0.05 vs. corresponding NS control group. Data adapted from Cohen et al. (34).

imply a renin-dependent pathway for the intracellular expres- sion of angiotensin peptides (65, 76, 106, 107, 142). Apart from its catalytic activity, prorenin may constitute an addi- tional circulating hormone of the RAS through binding and activation of the prorenin receptor within various tissues (52, 71, 94). A high molecular mass complex (50 – 60 kDa) com- prised of renin and the renin binding protein N -acetyl gluco- samine epimerase is typically revealed by immunoblot analy- sis; the complex renders renin inactive and may influence renin secretion (64). Regarding renin measurement, the enzyme is released by stress, dehydration, low-salt diet, RAS blockade, and certain anesthetics (pentobarbital sodium); therefore, phys- iological assessment of activity should ideally be obtained by rapid decapitation or blood withdraw by an indwelling catheter

in conscious animals. The classical method to detect renin activity is the direct generation of ANG I from angiotensinogen under assay conditions that protect ANG I from enzymatic degradation and does not attenuate renin activity. The assay requires a sensitive and quantitative method to detect the ANG I product at 10 12 g (pg) or 10 15 mol (fmol) typically by radioimmunoassay (RIA) or ELISA. To quantify the prorenin form, samples are enzymatically treated with trypsin to release the propeptide that occupies the active site and inhibits the enzyme; a trypsin inhibitor (i.e., soybean trypsin inhibitor) is then added before addition of the substrate. Prorenin activity constitutes the difference between the total or trypsin-activated renin and basal renin activity. Plasma contains high amounts of angiotensinogen; thus the assessment of plasma renin activity

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org




reflects both active renin and endogenous ANG I-angiotensino- gen in the circulation. Elased et al. (39) initially used surface- enhanced laser deabsorption ionization (SELDI)-mass spec- trometry (MS) to detect ANG I and demonstrate relative renin activity in very low volumes of plasma samples. Camenzind et al. (20) applied matrix-assisted laser deabsorption ionization-mass spectroscopy (MALDI-MS) to quantify ANG I generation from angiotensinogen with comparable renin activity values to that of RIA methods. Renin activity is typically expressed as nanograms or picomoles ANG I generated per milliliter of plasma per hour. Typical plasma renin activity values range from 0.5–10 ng·ml 1 ·h 1 ( 0.5–10 pmol·ml 1 ·h 1 ), whereas total renin (pro- renin/renin) is 3- to 10-fold higher reflecting the greater abun- dance of prorenin. Addition of exogenous angiotensinogen yields maximal renin activity that is conventionally but inappropriately termed plasma renin concentration. An alternative method is a direct human renin assay using capture and detection antibodies with the latter antibody directed to the active or open form of renin. In this regard, addition of the nonpeptide inhibitor aliskerin induces a conformation change in the enzyme that facilitates detection of prorenin by this assay (139). Using this method, van den Huevel et al. (139) reported mean values of active and prorenin at 14 pg/ml (0.4 pM) and 66 pg/ml (1.9 pM), respec- tively, in human plasma. Renin activity is also evident in the urine at 10% of the plasma levels of the enzyme (84, 139). In contrast to the circulation, there is little or no urinary prorenin, and this may reflect the predominant luminal secretion of renin from col- lecting duct cells (71, 82, 84, 92). Danser and colleagues (113, 139) suggest that urinary renin may be an alternative measure of an active RAS within the kidney. Quenched fluorescent substrates based on the ANG-(1–14) sequence are available to measure renin. Although this approach does not rely on the detection of ANG I or an exogenous source of angiotensino- gen, the sensitivity and specificity of the peptide substrates are not comparable with angiotensinogen. A protease/peptidase cocktail of inhibitors must be added to prevent nonspecific cleavage of the quenched substrate, as well as addition of a renin inhibitor such as aliskerin to demonstrate specificity of the assay. RAS peptidases. Peptidases are generally distinguished from proteases by their preference to hydrolyze peptides of 5 to 30 amino acids in length. In contrast to renin, the peptidases associated with the RAS do not exhibit exclusive specificity for angiotensins, although certain enzymes may exhibit preferen- tial kinetics such as ACE2 for ANG II (112, 145). An extensive peptidase class is the metalloenzymes [ACE, ACE2, neprilysin (Nep), aminopeptidase A] that require divalent cations for activity; thus the assessment of activity in the circulation is performed in serum in the absence of strong chelating agents such as EDTA or phenanthroline. ACE. The predominant pathway of the classical RAS is the hydrolysis of ANG I to ANG II by the metallopeptidase ACE, a dipeptidyl carboxypeptidase that cleaves two residues from the COOH-terminus of peptides. The peptidase is a membrane- bound and glycosylated protein (120 –180 kDa); however, soluble forms of the enzyme are present in the circulation, cerebrospinal fluid, lymph, and urine (15). ACE plays a key role in the formation of ANG II, but the peptidase metabolizes other peptides including bradykinin, substance P, acetyl-Ser- Asp-Lys-Pro, and ANG-(1–7) (16, 145). ACE activity is typ-

ically measured by small peptide substrates such as hippuryl- His-Leu or furylacrylol-Phe-Ala-Gly-Gly in a buffer contain- ing chloride (10 –200 mM) and zinc (1–100 M) for optimal peptidase activity (24, 122). Quenched fluorescent substrates Mca-Ser-Phe-Leu-Tyr-DNP or Mca-Tyr-Val-Ala-Arg-Ala-Phe- Lys-DNP have also been applied for ACE measurement; how- ever, these are not specific substrates and appropriate assay con- ditions that include an inhibitor cocktail to prevent nonspecific hydrolysis by other peptidases must be considered, as well as separate samples sets for an ACE inhibitor (i.e., captopril, lisino- pril) to confirm assay specificity (81). Finally, the degree of sample quenching of the fluorescent product should also be assessed for each source of activity. CHYMASE. Chymases comprise a family of serine peptidases that may form ANG II by hydrolysis of the Phe 8 -His 9 bond of ANG I and pseudoprecursors [ANG-(1–12), ANG-(1–25)] ( - chymases) or metabolize ANG II at Tyr 4 -Ile 5 to form ANG- (1– 4) and ANG-(5– 8) ( -chymases) (3, 27, 28, 89, 138). Humans express -chymase, whereas rodents express primar- ily -chymases, as well as other isoforms (mouse mast cell protease-4 and rat mast cell protease-5) that more closely resemble -chymase in regard to the processing of ANG I to ANG II (27, 28, 126). The human and mouse enzymes may also play a role in the conversion of the endothelin precursor to the active peptide, as well as the activation of various inflam- matory cytokines (28, 126). Chymases (35 kDa) are synthe- sized and stored in an inactive proform within mast cells and neutrophils that are released with other proteases (cathepsin G, tryptases, renin) upon degranulation following injury or in- flammation (28). Although chymases are soluble enzymes, they associate with the cell membrane and may locate to the extracellular surface of tissues following release. Fluorescent- quenched substrates for chymase include succinyl-Ala-Ala- Pro-Phe-amido-4-methylcoumarin and succinyl-Leu-Leu- Val-Tyr-amido-4-methylcoumarin. Addition of the serine protease inhibitor chymostatin is typically used to demon- strate specificity; however, chymostatin inhibits other ANG II-generating enzymes (cathepsin G, elastase-2) and more selective chymase inhibitors should be considered (116 – 118, 123, 146). The extent that chymase or other peptidases participate in the formation of circulating or tissue ANG II through an ACE-independent pathway remains an area of significant debate (21). ENDOPEPTIDASES. Nep ( 95 kDa) and other endopeptidases (thimet oligopeptidase, 80 kDa; and prolyl oligopeptidase, 76 kDa) process ANG I directly to ANG-(1–7) without the req- uisite formation of ANG II (Fig. 1). These peptidases hydro- lyze interior bonds of the peptide and prefer aromatic and/or hydrophobic residues, but prolyl oligopeptidase specifically cleaves the COOH-terminus of proline and hydrolyzes the Pro 7 -Phe 8 bond of both ANG I and ANG II to form ANG-(1–7) (29, 112, 145). Circulating forms of soluble Nep are present in the serum, urine, and cerebrospinal fluid (111, 129). Following chronic ACE inhibition, circulating levels of ANG-(1–7) are markedly higher that reflect processing of ANG I by vascular Nep, as well as the reduced metabolism by ACE (Fig. 1) (29). Various quenched substrates are available to measure Nep and other endopeptidases (81). The quenched peptide MCA-Arg- Pro-Pro-Gly-Phe-Ser-Ala-Phe-Lys-DNP may be an appropriate dual substrate for ACE and Nep (M. C. Chappell, unpublished observations). Again, the assay conditions require inhibitors to

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org





prevent nonselective hydrolysis of the substrate, as well the addition of a Nep inhibitor (thiorphan, SCH39370) to demonstrate specificity. Miners et al. (86) immunoprecipitated Nep before the addition of the fluorescent substrate, and this maneuver may enhance the specificity of the assay. This approach should be applicable to other peptidases provided the appropriate antibodies are available to pull down the enzyme and do not inhibit the active site. ACE2. ACE2 is a membrane-bound monocarboxypeptidase (120 kDa) that converts ANG II directly to ANG-(1–7). Cir- culating levels of ACE2 are typically quite low particularly compared with ACE; however, serum ACE2 activity is ele- vated in diabetes, heart failure, and hypertension (41, 136, 148). ACE2 has a potentially significant role in the RAS pathway as a single catalytic step degrades ANG II but acti- vates the ANG-(1–7) axis (Fig. 1) (29). ACE2 assays use the quenched fluorescent substrates Mca-Ala-Pro-Lys-DNP or Mca-Tyr-Tyr-Val-Ala-Asp-Pro-Lys-Dnp (111). These sub- strates are not specific for ACE2, and addition of other inhib- itors to block ACE, Nep and prolyl oligopeptidase, are critical to demonstrate assay specificity, as well as additional samples that include a specific ACE2 inhibitor (MLN4760, DX600). These fluorescent assays can be quantified for enzyme concentration given a standardized source of each peptidase is available (R&D Systems, Minneapolis MN). Using this approach, Rice et al. (111) reported the concentration of ACE in human serum averaged 7 nM in over 500 subjects, whereas ACE2 content was 200-fold lower (33 pM) and detectable in a minor fraction ( 10%) of this population. Circulating Nep content (290 pM) was also lower than ACE and evident in 30% of these patients (111). Aminopeptidases. The role of aminopeptidases in the RAS is generally considered a degradative pathway that initiates the metabolism of ANG II (Fig. 1). Recent studies suggest that the NH 2 -terminal processing of ANG II to ANG-(2– 8) or ANG III by aminopeptidase A may yield a peptide selective for brain AT 1 receptors and kidney AT 2 receptors (18, 25, 68, 103, 109). Further NH 2 -terminal processing of ANG III to ANG-(3– 8) or ANG IV yields another bioactive peptide that interacts with the insulin-regulated aminopeptidase (4). Fluorescent substrates are available for aminopeptidases A and N as well as general (amastatin, bestatin) and more selective inhibitors to distin- guish these enzymes (18). Peptidase assays. Endogenous peptide substrates including ANG I, ANG II and ANG-(1–12) can be directly used to quantify peptidase activities (79). One advantage is that the contribution of various peptidases for a given peptide can be directly compared to determine the predominant activity in a particular tissue or treatment. In contrast, peptidase activities derived by different synthetic substrates are not directly com- parable unless standardized to enzyme content. Moreover, use of endogenous peptides may reveal novel peptidase activities involved in angiotensin processing (62, 144). Peptidase assays developed in the author’s laboratory use 125 I-radiolabled pep - tides coupled to HPLC-based separation and in-line -detec- tion (129). Typically, microliter amounts of serum or micro- gram quantities of tissue are required with this approach. We find that circulating ACE and ACE2 activities were signifi- cantly increased in a model of diabetic hypertension; however, ACE activity remained far higher than ACE2 which may contribute to the greater content of ANG II in diabetic

mRen2.Lewis rats (148). Kinetic analysis using both labeled and unlabeled ANG II confirmed a sevenfold increase in the V max value for serum ACE2 in the female diabetic rat (148). Angiotensin processing in tissues, cells, and plasma was recently assessed by HPLC-MS. Hildesbrand et al. (62) used a HPLC-tandem quadropole system (HPLC-MS/MS) to reveal metabolism pathways from ANG I to its NH 2 -terminal metab - olites ANG-(5–10) and ANG-(4 –10), as well as ANG II and ANG-(1–7) in immobilized proteins from plasma. Suski et al. (133) find that ANG I was primarily converted to ANG-(1–7) in vascular smooth muscle cells (VSMC) by HPLC-MS/MS and support an earlier study (32) that thimet oligopeptidase directly processed ANG I to ANG-(1–7) in rat VSMCs. Fi- nally, Grobe and colleagues (6, 53) applied in situ MALDI to characterize both renal and cardiac metabolism of exogenous ANG II. In this approach, ANG II was incubated on the tissue surface and the MS matrix subsequently layered over each tissue section. The matrix was subjected to MALDI-MS anal- ysis, and the metabolism products were identified and localized to distinct areas of the kidney. ANG-(1–7) was the primary product from ANG II in the renal cortex, whereas ANG III was the major metabolite in the medulla (53). In the heart, ANG III and ANG-(1–7) were major products of ANG II metabolism, catalyzed by aminopeptidase A and ACE2, respectively (6). These data confirm earlier HPLC-based studies on the contri- bution of ACE2 to ANG-(1–7) formation in the mouse and human heart (49, 152). Caveats with this approach are that MALDI-MS cannot distinguish intracellular versus membrane or extracellular processing and requires relatively high sub- strate concentrations to detect peptidase activity that may not reflect endogenous processing pathways. However, given the rapid advancement of this technology, future systems will likely develop the required sensitivity and resolution to appro- priately detect peptides in situ, as well as characterize the extent of enzymatic processing. Receptors. ANG II and ANG III interact with two G protein- coupled receptors identified as the AT 1 and AT 2 subtype, whereas ANG-(1–7) and [Ala 1 ]-ANG-(1–7) recognize the Mas and Mas-related G protein-coupled receptor member D (mRG-D) receptors, respectively (12). Immunoblot techniques can provide a relative quantification of protein expression, as well as tissue and cellular distribution; however, the commer- cially obtained AT 1 and AT 2 receptor antibodies are notorious for their nonspecific nature (59, 61). Receptor antibody spec- ificity is complicated by 1 ) posttranslational processing events such as glycosylation or proteolysis that may yield unexpected molecular size bands for the receptor in different tissues or species, 2 ) the very low level of receptor expression particu- larly compared with other RAS proteins, and 3 ) the lack of appropriate controls for each antibody. The sole reliance on antibody-based immunoblot methods to assess receptor expres- sion underlies the need to standardize the receptor antibodies to ensure some degree of reproducibility among laboratories. Issues with antibody specificity are certainly not limited to the RAS components and present a major concern regarding the unreliability of antibodies against their intended targets (13). Indeed, the National Institutes of Health has recently promoted a more rigorous approach to ensure reliability and overall reproducibility in preclinical experimental studies (http:// www.nih.gov/science/reproducibility/). Uses of knockout trans- genic mice, knockdown approaches in cells, or overexpression of

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org




the target protein are appropriate controls to test antibody speci- ficity for immunoblot and immunocytochemistry methods, al- though these approaches are not directly comparable with other species or different tissues. Moreover, knockdown of the func- tional domain does not ensure that the remaining protein will not be recognized by the antibody. Blockade of the immunoreactive signal by the immunizing peptide or full-length protein is an additional approach to address specificity of the immunoblot or immunocytochemistry signal provided a pure source of the pep- tide/protein is available; however, antigenic sites exposed by SDS denaturation, formalin fixation, or antigen retrieval may not be accessible for proteins in solution. The characterization of angiotensin receptors is further complicated by the fact that these proteins do not reside or exclusively localize to the plasma membrane. In lieu of earlier studies on intracellular peptide receptors, ANG II and ANG-(1–7) receptors were characterized on isolated nuclei from rat and sheep kidney (54). In rat nuclei, binding studies with the nonselective antagonist 125 I-[sarcosine 1 , threonine 8 ]-ANG II (sarthran) and competition with selec - tive antagonists revealed exclusive expression of the AT 1 receptor (104, 105) (Fig. 3, A–C ). Fluorescence-activated cell sorting demonstrated essentially complete overlap of the fluorescent signature for the AT 1 receptor and the nuclear marker nucleoporin; the immunoblot confirmed a single protein band for the renal nuclei with the same AT 1 R

antibody (Fig. 3, D–E ). Functional studies revealed that ANG II stimulated reactive oxygen species and was blocked by both an AT 1 R antagonist and a NAD(P)H inhibitor (Fig. 3 F ). A similar approach was taken for the AT 7 /Mas receptor in isolated nuclei of the sheep kidney (55–58). An alomone antibody (Alomone Labs, Tel Aviv, Israel) revealed Mas receptor expression along the tubular elements of the kidney that was abolished by antibody preabsorption with the immunogenic peptide; a single band ( 35 kDa) was evident on the full-length immunoblot of isolated nuclei (Fig. 4, A–F ). Competition of sarthran binding in nuclei revealed complete additivity with the AT 1 R antagonist losartan and the AT 7 R antagonist [ D -Ala 7 ]-ANG-(1–7) (A779), but par - tial additivity with the AT 2 R antagonist PD123319 suggest - ing the AT 7 R and AT 2 R antagonists are not entirely selec - tive for the sarthran ligand (Fig. 4 G ). However, only the [ D -Ala 7 ]-ANG-(1–7) antagonist and the nitric oxide syn - thase inhibitor N G -nitro- L -arginine methyl ester abolished the ANG-(1–7)-stimulated release of nitric oxide on renal nuclei as detected by diaminofluorescein fluorescence (Fig. 4 H ). In regard to the AT 2 R, Padia et al. (103) find that the receptor protein resides primarily in the cytosolic compart- ment and rapidly inserts into the apical membrane of the proximal tubules following dopaminergic stimulation to facil- itate a natriuretic response. Interestingly, translocation of the AT 2 R in spontaneously hypertensive rats was blunted com -

2 R in spontaneously hypertensive rats was blunted com - Fig. 3. Characterization of AT 1

Fig. 3. Characterization of AT 1 Rs in isolated nuclei from the rat renal cortex. A : saturation binding with the antagonist 125 I-Sar 1 , Thr 8 -ANG II (sarthran) in isolated renal nuclei. B : scatchard analysis of sarthran binding revealed a K D of 0.7 nM and a B max of 270 fmol/mg protein. C : competition studies revealed inhibition of binding with AT 1 antagonists losartan (Los), candesartan (CV), but not the AT 2 antagonist PD123319 (PD) or the AT 7 /Mas receptor antagonist D -Ala 7 -ANG-(1–7) (DALA). D : cell sorting of isolated renal nuclei revealed essentially complete overlap of the nuclear marker nucleoporin 62 (Nup62) and the AT 1 R. PE, phycoerythrin. E : immunoblot of renal nuclei with the AT 1 R antibody revealed a single 52-kDa band. MS, molecular size. F : ANG II stimulates oxidative stress in renal nuclei measured by the increased fluorescence with the dichlorofluorescein (DCF) probe. ANG II-dependent stimulation was blocked by Los and the NAD(P)H oxidase inhibitor diphenyleneiodonium (DPI). ROS, reactive oxygen species. * P 0.05 vs. control or ANG II-treatment. Data adapted from Pendergrass et al. (104, 105).

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org





  Review ASSESSMENT OF THE RAS H143 Fig. 4. Characterization of the AT 7 /Mas re
  Review ASSESSMENT OF THE RAS H143 Fig. 4. Characterization of the AT 7 /Mas re
  Review ASSESSMENT OF THE RAS H143 Fig. 4. Characterization of the AT 7 /Mas re

Fig. 4. Characterization of the AT 7 /Mas re - ceptor in the kidney and isolated nuclei from the sheep renal cortex. A–C : immunofluo- rescent staining for the AT 7 /Mas receptor (Alomone antibody) in proximal tubules (PT), collecting duct (CD), vasa recta (VR) and thick ascending limb (TAL) but not glomeruli (GM) or distal tubule (DT) in the sheep kidney. D–E : absence of ICC staining by preabsorption with the Mas immuno- genic peptide in adjacent sections. F : single protein band in isolated nuclei from sheep cortex revealed by Alomone Mas antibody in full-length gel. G : competition for sar- thran binding on isolated nuclei from sheep renal cortex. The AT 7 /Mas receptor antago- nist DALA and AT 1 R antagonist Los exhibit complete additivity for competition of sar- thran binding. In contrast, the AT 2 antago - nist PD exhibits partial additivity with DALA. Mean values of percent competition are given above each bar. H : ANG-(1–7)

(A7) stimulates nitric oxide (NO) release (increased DAF fluorescence) that was blocked by DALA and the nitric oxide synthase inhibitor N G -nitro- L -arginine methyl ester but not by Los or PD. * P 0.05 vs. ANG-(1–7)-treatment. Data adapted from Gwathmey et al. (57, 58).

pared with normotensive Wistar-Kyoto rats (103). Biotinyla- tion studies combined with an AT 2 R antibody was used to reveal localization of the receptor on the plasma membrane (103). It is not currently known whether the other angiotensin receptor subtypes exhibit a similar type of regulation. In this regard, a careful assessment of the subcellular fractions or intracellular organelle for angiotensin receptor expression is warranted. Moreover, these and other studies support the in- tracellular expression of G protein-coupled receptors within the kidney and other tissues, as well as emphasize the necessity for multiple approaches in the identification and characterization of angiotensin receptors (17, 35, 40, 74, 132, 151).

RAS Peptides

Interest in angiotensins other than ANG II and ANG III was stimulated by identification of endogenous ANG-(1–7) over 25 years ago (30), as well as subsequent evidence for an ANG- (1–7) receptor (121) and a converting enzyme (137). [Ala 1 ]- ANG II and [Ala 1 ]-ANG-(1–7) were recently identified in human plasma, likely arising from decarboxylation of the

NH 2 -terminal aspartic acid residue (67, 75). Functionally, [Ala 1 ]-ANG II may not distinguish AT 1 or AT 2 receptors (67, 149), whereas [Ala 1 ]-ANG-(1–7) recognizes the Mas-related receptor mRG-D to induce vasorelaxation (12, 75). Both [ D -Pro 7 ]-ANG-(1–7) and the AT 2 antagonist PD123319 blocked the actions of [Ala 1 ]-ANG-(1–7), but not [ D -Ala 7 ]- ANG-(1–7) (75). Jankowski et al. (66) identified [Pro 1 , Glu 2 ]-ANG II in human plasma and this peptide exhibits a greater affinity for the Mas receptor than ANG-(1–7); how- ever, the pathway for the peptide’s formation is unknown. The ANG II metabolite ANG-(3– 8) or ANG IV has distinct func- tional properties through the interaction with the insulin-regu- lated aminopeptidase, although the peptide also stimulates the AT 1 R (4, 80, 150). ANG-(1–9), a potential product of ACE2 processing of ANG I, appears to functionally interact with the AT 2 receptor (101). Finally, Nagata and colleagues (89, 90) identified the intermediate precursors ANG-(1–12) in rat and ANG-(1–25) in human urine. ANG-(1–12) is processed by ACE and chymase to ANG II, and Nep directly generates ANG-(1–7), whereas ANG-(1–25) is converted by a chymase-

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org




like enzyme to ANG II (3, 89, 143). The circulating and tissue pathways for the generation of ANG-(1–12) and ANG-(1–25) are not currently known but are likely renin independent. The accurate assessment and identification of angiotensins are critical to ascertain the status of the RAS, particularly in pathological conditions or following therapeutic intervention; however, their evaluation is hampered by the extremely low level of peptide expression in the fentomole per gram or fentomole per milliliter range, interfering substances in sam- ples that may be present at a far higher concentration, suscep- tibility to metabolism in sample collection and processing, the peptides’ shared sequence, and the specificity of detection. All these factors may contribute to the marked variability in angiotensin values evident in the literature and raise concerns on the identity of ANG II or other angiotensins detected in tissues and the circulation, as well as the extent that altered peptide content truly reflects or contributes to a particular phenotype or treatment response. RIA/ELISA. RIA and ELISA are invaluable assays to char- acterize angiotensins, and they remain the most used biochem- ical methods to quantify endogenous peptides. Under optimal assay and extraction conditions, both methods should allow for the sensitive and relatively specific detection of ANG II and other angiotensins at fentomole (pg) quantities in plasma, tissue, urine, and cells. Since angiotensins share an identical NH 2 -terminus except for the Ala 1 -forms of ANG II and ANG- (1–7), antibodies for ANG II, ANG-(1–7), ANG-(1–9), ANG I, and ANG-(1–12) are directed against their unique COOH- terminus. The ANG II and ANG-(1–7) antibodies, for example, typically distinguish a single amino acid difference (Phe 8 ) between ANG II and ANG-(1–7). Importantly, these antibodies are not selective against the NH 2 -terminal portion of the peptide (30). Thus an ANG II RIA distinguishes ANG-(1–7) and ANG I but will recognize ANG III, ANG IV, and ANG- (4 – 8) (37). Similarly, an ANG-(1–7) antibody recognizes the NH 2 -terminal metabolites ANG-(2–7) and ANG-(3–7), but not ANG-(4 –7), ANG II, or ANG I (30). These assays can be used across species as the COOH-terminal portion is conserved for ANG-(1–7), ANG II, and ANG I; however, larger peptides such as ANG-(1–12) or ANG-(1–25) exhibit different COOH- terminal residues that are species specific and require unique antibodies for detection (89, 90). Apart from their nonselec- tivity for NH 2 -terminal metabolites of angiotensin peptides, RIA or ELISA may detect a significant degree of nonspecific or background immunoreactivity that reflects the sample source and extent of purification or extraction, as well as the assay antibodies (37). Therefore, chromatographic separation should be routinely coupled to RIA or ELISA to verify the identity of immunoreactive peptides, as well as account for nonspecific material in plasma or tissue samples. Peptide fractionation by HPLC provides this additional level of discrimination based on the resolution and high recovery of the sample peptides, rapid separation time, and general compatibility with RIA methods (22, 30, 37, 78, 99). In addition, the different characteristics for each antibody-based assay must be appreciated, particularly those obtained from commercial sources. The stated cross- reactivity of the Peninsula human ANG-(1–12) ELISA for ANG I is 0%; however, the Peninsula rat/mouse ANG-(1–12) ELISA cross-reacts 60% with ANG I (Peninsula Lab Int, San Carlos, CA). Thus HPLC fractionation would be essential to

distinguish endogenous ANG I and ANG-(1–12) content in the rodent with the Peninsula ELISA. We previously reported that renal ANG II content declined 80% in mice that lack membrane ACE, a transgenic model developed by Bernstein and colleagues (88) that expresses soluble but not the tissue-bound enzyme. ANG II content was quantified directly by a commercial ANG II RIA (ALPCO Diagonostics, Salem, NH) that recognizes ANG III, ANG IV, and ANG-(4 – 8), whereas ANG-(1–7) was detected by a cus- tom RIA that also detects ANG-(2–7) and ANG-(3–7) (30). Renal tissue was extensively extracted with cold HCl-ethanol, proteins precipitated by heptafluorobutyric acid (HFBA) and peptides purified on C18 SepPak columns (30, 88). To confirm ANG II identity, pooled renal extracts were fractionated by HPLC using the HFBA system developed in the author’s laboratory that achieves baseline separation of immunoreactive angiotensins, and the fractions were assayed by separate RIAs (30). ANG II was the primary immunoreactive peak in both the wild-type (WT) and transgenic ACE / mice, but the ANG II peak was markedly lower in the ACE-deficient mice (Fig. 5). Note that ANG III and ANG-(4 – 8) represent minor immuno- reactive peaks that are essentially absent in the transgenic kidney. Renal ANG-(1–7) content was unchanged despite the marked reduction in ANG II and suggests that a non-ACE2 pathway contributes or maintains tissue ANG-(1–7) (Fig. 5). Overall, this approach confirmed that the two RIAs identified predominantly NH 2 -terminally intact ANG II and ANG-(1–7) in the mouse kidney, as well as demonstrate the greater ratio of ANG II to ANG-(1–7) in the WT kidney. However, these results do not ensure that ANG II or ANG-(1–7) RIAs primar- ily detect both peptides in all experimental situations and verification of the direct assay values is essential for each tissue source and species. Campbell and colleagues (22–24, 78) developed an alterna- tive approach with RIAs specific to the NH 2 -terminus of intact and smaller metabolites rather than the COOH-terminus of angiotensins. To distinguish peptides that differ in their COOH-terminal sequence, samples are extracted in guanidine thiocynate, acetylated, subjected to HPLC separation, and the fractions analyzed by the different NH 2 -terminally-specific RIAs. An advantage of the approach is that all peptides that share the identical NH 2 -terminus [i.e., ANG I, ANG II, and ANG-(1–7)] are assayed by one RIA antibody rather than multiple assays, and all reported values reflect HPLC fraction- ation. Disadvantages of the HPLC-RIA approach are the re- quired equipment, expertise, and the lack of an automated method for analysis and that HPLC separation generates a significantly larger sample size for RIA or ELISA quantifica- tion. Moreover, the NH 2 -terminal RIAs are not commercially available and cannot be applied for direct peptide measure- ments. Finally, it is not clear whether HPLC-RIA can resolve [Ala 1 ]-isoforms or other posttranslational modifications of ANG II and ANG-(1–7). LC-MS/MS. RIA and ELISA exhibit the requisite sensitivity and specificity to detect endogenous angiotensins; however, these methods are highly dependent on the characteristics for each antibody, as well as the optimal sample extraction and assay conditions. Angiotensin RIAs or ELISAs are typically directed against the unique COOH-terminus of the peptide, and they fail to distinguish the NH 2 -terminal metabolites unless coupled to HPLC. LC-MS/MS directly detects peptides based

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org





  Review ASSESSMENT OF THE RAS H145 Fig. 5. Characterization of ANG II and ANG-(1–7) in

Fig. 5. Characterization of ANG II and ANG-(1–7) in the mouse kidney by HPLC- RIA. HPLC/RIA analysis of pooled mouse

kidney extracts from wild-type (WT; A ) and tissue ACE knockout (tisACE / mice; B ). The HPLC fractions were measured with ANG-(1–7) (fractions 1–20) and ANG II

( fractions 21– 40) RIAs, respectively. Ar-

rows indicate the elution peak times for ANG-(1–7), ANG-(3–7), ANG-(4 – 8), ANG II, and ANG-(2– 8) or ANG III. C : reduced total ANG II content in tisACE / kidney but no change in total ANG-(1–7) levels as determined by direct RIAs. D : proportion of ANG II and ANG-(1–7) and their metabo- lites in the mouse WT kidney from HPLC- RIA analysis. Intrarenal concentration of ANG II and ANG-(1–7) was expressed as fmol/mg protein in WT and tisACE /

mice. * P 0.05 vs. WT. Adapted from Modrall et al. (88).

on their unique mass to charge spectra and exhibits the capa- bility for quantification of endogenous peptides (83). Unlike the antibody-based RIA or ELISA, MS can potentially resolve posttranslational events such as peptide phosphorylation, ami- dation, acetylation, decarboxylation, or other peptide forms. Extracted samples are initially resolved by a chromatographic step [HPLC, ultrahigh-pressure LC (UPLC), or nano-LC], the eluent volatized, and the peptide or resultant fragment ions detected by MS [single or tandem, time of flight (TOF), ion trap, or their combination]. A key issue with MS is that a number of components are detected following the LC separa- tion and may render very complex spectra with similar mass- to-charge ratios, particularly as the prior chromatographic step does not resolve all individual peptides, and endogenous pep-

tides are typically 10 3 -10 9 less abundant than other species in plasma and tissues (11, 83). To address this issue, Schulz et al. (125) developed a hybrid approach to selectively enrich ANG

II from plasma extracts by absorption to an ANG II antibody

before quantification by HPLC-MS/MS. These investigators quantified ANG II at 20 fmol/ml (20 pM) in human plasma that is comparable wth RIA or HPLC-RIA values, although

other NH 2 -terminal metabolites of ANG II were not reported (125) (Table 1). Addition of isotopically labeled ANG II is key

in the MS approach to account for extensive sample handling

and extraction, as well as the extent of peptide ionization. Poglitsch and colleagues (60, 108) have recently developed a “fingerprint” HPLC-MS/MS approach to quantify 10 angio- tensins in plasma with a comparable sensitivity to RIA; how- ever, the addition of exogenous renin is apparently required for peptide measurements in human plasma. HPLC-MS/MS may

potentially become the standard method to quantify angio- tensins, although the complexity, expertise, and cost required

for these systems are limiting factors for most laboratories at the current time. The fingerprint MS is available as a fee for service to quantify angiotensins in plasma and tissues (At- toquant, Vienna, Austria). Other approaches. Additional methods to quantify angioten- sin peptides in plasma and tissues include direct HPLC and capillary electrophoresis. Both methods are based on the direct determination of angiotensins by ultraviolet absorp- tion (UV, 180 –220 nm) following an initial chromato- graphic or electrophoretic separation. The concerns here are that neither approach achieves complete separation of all peptides (angiotensin and non-angiotensin), and UV detec- tion does not discriminate among the peptide milieu in contrast to RIA, ELISA, or MS methods. Therefore, a UV peak may be comprised of multiple species, and alterations in peak area between experimental groups cannot be readily attributed to one peptide. Moreover, the reported sensitivity or limit of quantitation of 3 pmol for the HPLC analysis is not adequate to detect authentic levels of endogenous pep- tides (16). ANG II and ANG-(1–7) values derived from these methods are typically far higher in plasma (26, 33, 51, 135), kidney (33, 110, 114), vasculature (48), adipose tissue (33, 115), and heart (42) than by RIA, HPLC-RIA, or HPLC-MS methods (Table 1). Indeed, two recent studies quantified mouse renal ANG-(1–7) at 1,000,000 fmol/g tissue (110) and rat plasma ANG II at 300,000 pM by HPLC analysis alone (33). Rubio-Ruiz et al. (115) reported an ANG-(1–7) concentration of 6,000 pM in serum and 500,000 fmol/g in adipose tissue from male Wistar rats by capillary electrophoresis. Sample handling and extraction. Appropriate handling and subsequent extraction of plasma and tissue samples cannot be

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org




overly emphasized for the accurate measurement of endoge- nous angiotensins. Regardless of the detection method by RIA, HPLC-RIA, or HPLC-MS, improper sampling handling and extraction may yield artifactually high or low peptide values that do not reflect endogenous content. The sensitivity required to quantify endogenous angiotensins also increases the poten- tial for artifacts or interfering substances whether using RIA or MS approaches. In general, animals should be maintained in a calm environment and anesthetic agents such as pentobarbital sodium that markedly activate the RAS avoided. Blood sam- ples are collected directly into an inhibitor cocktail to block renin and other peptidases that process or metabolize angio- tensin peptides; the obtained plasma should be subsequently stored at 80°C or immediately extracted. Tissue samples should be rinsed of blood and rapidly frozen in liquid nitrogen or an ethanol-dry ice bath or immediately extracted. Pepstatin, an aspartyl protease inhibitor, may not be sufficient to com- pletely block renin activity, and a more specific renin inhibitor should be considered (73, 98). Moreover, the typical inhibitor cocktails for protein immunoblot analysis may be inadequate to attenuate angiotensin processing of samples in physiological buffers. Various extraction methods that rapidly abolish peptide metabolism, deplete the sample of contaminating proteins and other substances that may interfere with the assay and enrich peptide content in a manageable volume include acid (HCl)- ethanol, pure methanol or acetonitrile, guanidine thiocynate, and immediate immersion in a boiling water bath with subse- quent acidification and tissue homogenization (22, 24, 30, 37, 90, 130). The precipitated proteins are removed by high-speed/ ultracentrifugation or molecular cut-off filters, and the super- natant is applied to solid-phase extraction columns (C18 or phenyl). Both angiotensin and nonangiotensin peptides are absorbed to these columns, whereas proteins and other sub- stances are not retained; the peptides are subsequently eluted in an organic solvent (methanol or acetonitrile). Peptides stan- dards (i.e., 125 I-ANG II, ANG II, or isotopically labeled ANG II) should be routinely added to determine overall recovery in the extraction procedure for quantification methods, and par- ticularly to account for matrix effects on MS ionization that may vary among samples or MS analysis runs. Recovery for plasma samples typically ranges from 70 to 90%, whereas tissues are generally lower in the 40 –70% range. Appropriate blanks must be included that contain all components of the extraction method (apart from the actual sample) and assayed in parallel with samples. Angiotensin values. The range of angiotensin values for plasma and tissues in Table 1 reflects studies using HPLC-RIA or HPLC-MS quantification, as well as consideration of the appropriate sample collection and extraction methods (22–24, 37, 85, 97–100, 127, 128). In lieu of these approaches, the NH 2 -terminally intact forms of ANG II, ANG-(1–7), and ANG I are the predominant peptides identified in plasma and various tissues. Quantitation of the cell and urinary data reflects direct RIA- or ELISA-based methods (9, 34, 38, 45, 50, 70, 77, 115, 131, 133, 139, 141, 148). CIRCULATION. ANG II values in human, mouse, and rat plasma are quite low and average 5–50 fmol/ml (5–50 pM) (Table 1). Human plasma levels of the ANG II isoforms [Ala 1 ]-ANG II and [Pro 1 , Glu 2 ]-ANG II average 6 and 4 pM, respectively, as quantified by MALDI (66, 67). Circulating

ANG-(1–7) values exhibit a similar range to ANG II, although the peptide is markedly increased following ACE inhibitor treatment, whereas endogenous levels of the ANG-(1–7) iso-

form [Ala 1 ]-ANG-(1–7) have not been quantified (Table 1). ANG I values are somewhat higher than ANG II, provided renin activity is attenuated during the sample collection and processing, whereas ANG-(1–9) levels are very low (Table 1). Adequate plasma volumes to detect these peptides in this range require 3 to 5 ml of extracted plasma (4 –10 ml blood) to assay. In regard to the MS analysis of circulating angiotensins, the peptide profile reported by Poglitsch and colleagues (60, 108) is difficult to interpret as addition of exogenous renin to human plasma samples is apparently necessary to quantify circulating angiotensin peptides. This approach does not reflect the actual angiotensin content in the circulation as renin addition fails to account for the contribution of membrane-bound peptidases (i.e., Nep, ACE2, ACE, APA) nor the vascular release of angiotensin peptides (31, 63, 87). Wysocki et al. (147) recently evaluated plasma angiotensins from male WT mice by the fingerprint MS method without the addition of renin. Surpris- ingly, plasma levels of ANG III greatly exceeded ANG II (1,130 vs. 7 pM), whereas similar levels of ANG I and ANG-(2–10) (1,000 and 700 pM) were reported (147). Little detail was provided on the extraction method or inhibitors employed, and the high plasma content of ANG III and ANG-(2–10) may reflect inadequate blockade of aminopepti- dase activity particularly given the use of the anesthetic pen- tobarbital (147). Indeed, their additional analysis of plasma peptides from female WT mice anesthetized with ketamine revealed far lower plasma ANG III, although the levels of ANG III were twofold higher than ANG II (160 vs. 74 pM) (147). Olkowicz et al. (102) quantified plasma angiotensin by MS in male WT mice and in apolipoprotein E / mice that exhibit a stimulated RAS. Plasma levels of ANG II, ANG III, and ANG-(1–7) were 36, 32, and 63 pM, respectively; how- ever, ANG IV (158 pM) was the predominant peptide in WT mice (102). ANG II and its COOH-terminal intact metabolites were elevated 3- to 10-fold in the apolipoprotein E / mice, but ANG IV remained the major peptide (550 pM); plasma levels of ANG-(1–7) were unchanged (102). Although the ANG II and ANG-(1–7) values were comparable with RIA- based studies, the higher ANG III and ANG IV content may again reflect inadequate inhibition of aminopeptidases by addition of a standard protease inhibitor cocktail in contrast

to extraction methods specifically designed to inhibit pep-

tide processing (102). Finally, Ali et al. (7) quantified

plasma ANG II and ANG-(1–7) content at 20,000 and 40,000 pM, respectively, in WT mice using UPLC-quar- druple (Q)TOF. The presence of other ANG II or ANG-

(1–7) metabolites were not reported, but the extreme ANG

II and ANG-(1–7) values by this method likely reflect

inadequate inhibition of plasma peptidases during blood collection and extraction (7). Tissues. Tissue expression of angiotensins is widespread;

however, there are marked differences in the tissue content of these peptides (Table 1). The adrenal typically expresses the highest content of ANG II from 300 to 2,000 fmol/g tissue with

far lower levels of ANG III and ANG-(1–7) (Table 1). ANG II

content in other peripheral tissues including the kidney, lung, and liver average of 100 to 700 fmol/g (Table 1). Within the rat kidney, ANG II, ANG-(1–7), and ANG I levels were higher in

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org





the medulla than the cortex (direct RIAs) (91, 104); Pender-

grass et al. (104) confirmed the predominant ANG II identify in both cortex and medulla by HPLC-RIA. In comparison, sig- nificant levels of ANG II ( 300 fmol/g tissue) were quantified

in the ovary and uterus by Senanayake and colleagues (37).

Apart from these tissues, central and peripheral tissues includ- ing the heart and adipose express lower and somewhat more variable ANG II levels of 2–150 fmol/g tissue (Table 1). In regards to MS analysis, few studies have quantified ANG

II and ANG-(1–7) in tissue. Ali et al. (7, 8) reported ANG II

and ANG-(1–7) levels of 200,000 and 350,000 fmol/g in mouse kidney and 25,000 to 60,000 fmol/g tissue in rat kidney cortex by UPLC-QTOF (7, 8). They also quantified ANG II

and ANG-(1–7) content in mouse adipose tissue at 150,000 and 350,000 fmol/g tissue, respectively (7). It is difficult to recon- cile that the kidney and adipose exhibit the same synthetic capacity to generate essentially identical levels of ANG II or ANG-(1–7). Moreover, extraction of tissue with a very high protease content such as the kidney in a Tris lysis buffer at neutral pH is likely insufficient to abolish processing and may contribute to the high peptide content reported for kidney (7, 8). The stated limit of quantitation for the UPLC-QTOF for ANG II (500 fmol) and ANG-(1–7) (800 fmol) also does not appear adequate to quantify the authentic peptide content in plasma and tissues (7). In contrast to the Ali studies, Wysocki

et al. (147) quantified far lower levels of ANG II and ANG-

(1–7) (293 and 95 fmol/g tissue, respectively) in the mouse kidney by fingerprint MS; these values are clearly more con- sistent with the literature, although the ANG III content (185 fmol/mg tissue) was relatively high at 60% of the total ANG II (Fig. 5, Table 1). Finally, Burger et al. (19) found a higher ANG II-to-ANG III ratio (700 vs. 130 fmol/g tissue) in mouse kidney using guanidine extraction and MS. In this case, gua- nidine may attenuate aminopeptidase and other peptidase ac- tivities more effectively to prevent the artifactual generation of peptides during tissue extraction.

INTERSTIAL CONTENT. The extracellular or interstial content of ANG II in heart and kidney was assessed by direct RIA and HPLC-RIA. These studies use an implanted dialysis probe permeable to low molecular substances that sample the local release or formation of angiotensin peptides in the interstial space. Dell’Italia and colleagues (14, 36) reported interstial ANG II levels in the canine heart at 0.6 to 5 pmol/ml (0.6 –5 nM) by HPLC-RIA. Intravenous infusion of ANG I alone or combined with an ACE inhibitor did not impact the interstial ANG II levels. Schuijt et al. (124) found low to undetectable levels of ANG II ( 30 fmol/ml or 30 pM) in interstial fluid of the ovine heart also quantified by HPLC-RIA. In the rat kidney, Kemp et al. (68) report comparable ANG II and ANG III interstial content ( 80 fmol/ml or 80 pM) using the HFBA- HPLC system to separate the two peptides before RIA detec- tion. This study finds a higher ANG III-to-ANG II ratio than that in the circulation or tissues, which may reflect the signif- icant level of ectocellular APA activity in the renal tubules and suggests significant angiotensin processing in the interstial space. Finally, Nishiyama et al. (95, 96) reported higher renal interstial levels of ANG II and ANG I (1–3 nM) by direct RIAs. The interstial ANG II levels were not responsive to peripheral ACE inhibition or volume expansion, further sug- gesting a local mechanism of peptide expression distinct from

the circulation, albeit the identity of ANG II or ANG I immunoreactivity was not established in these studies (95, 96). URINE. The urinary components of the RAS are of interest regarding their potential application as biomarkers of renal injury or RAS activation (5, 72, 113). Although excretion of the RAS proteins including angiotensinogen, renin, and ACE2 are more routinely assessed, the urinary levels of ANG II and ANG-(1–7) were quantified by direct RIA or ELISA (Table 1). Urine contains multiple peptidase activities, and the samples should be collected under conditions that limit ex vivo metab- olism (acidification, addition of inhibitors, or collection on dry ice) (50). Chan and colleagues (131) reported higher ANG II excretion in the diabetic Akita mice compared with WT ( 25 vs. 2 pmol/mg Cr), whereas urinary ANG-(1–7) levels were 50% lower in the diabetic mice (3 vs. 7 pmol/mg Cr), suggesting an imbalance of ANG II to ANG-(1–7) in the diabetic kidney; these peptides were quantified by Bachem ELISAs (Torrance, CA). Gilliam-Davis et al. (50) quantified ANG II (0.4 pmol/mg Cr) and ANG-(1–7) (0.2 pmol/mg Cr) in adult male Fisher 344 rats by direct RIAs. Both ANG II and ANG-(1–7) excretion increased twofold in aged Fisher rats, suggesting activation of the renal RAS in this model of aging. Chronic treatment with an AT 1 R antagonist lowered the ex - cretion of both peptides despite a marked increase in circulat- ing angiotensins and further distinguishes compartmentaliza- tion of the renal and circulating RAS (50). Urinary levels of both ANG II and ANG-(1–7) were elevated in female and male mRen2.Lewis on the HS diet; however, ovariectomy of the hypertensive females did not increase peptide excretion despite

a 20-fold increase in urinary angiotensinogen (Fig. 2) (34).

Finally, ANG-(1–7) excretion was significantly lower in a cohort of hypertensive patients compared with the normoten- sive group (0.05 vs. 0.11 pmol/mg Cr) using a custom RIA to quantify ANG-(1–7); ANG-(1–7) identity in human urine was verified by HPLC-RIA (45).

CELL MODELS. In an extensive analysis of angiotensin regu-

lation in rat VSMCs using direct RIAs (Peninsula), Lavrentyev et al. (77) reported that ANG II content increased threefold

( 50 to 150 fmol/mg protein) in response to high glucose

conditions. ANG II content also increased in the cell media with high glucose (100 to190 fmol/ml). In contrast, basal ANG-(1–7) (260 fmol/mg protein) was higher than ANG II, and ANG-(1–7) content was reduced fivefold under hypergly- cemic conditions that was also associated with a reduction in ACE2 (77). In a human mesangial cell line, Boim and col- leagues (141) reported comparable ANG II levels (150

fmol/mg protein), as well as secreted ANG II in the media (30 fmol/mg protein after 24 h) using a Peninsula ELISA. Basal ANG II levels were also similar (180 fmol/mg protein) in immortalized mouse podocytes, and peptide content increased with mechanical strain (38). Singh and colleagues (132) quan- tified ANG II content at 200 fmol/mg protein in cultured neonatal cardiomyocytes and fibroblasts; the cellular ANG II levels were also markedly elevated by high glucose conditions and exhibited a greater nuclear localization for ANG II. ANG

II content was determined by a direct Peninsula ELISA, and

the relative peptide expression in control and high glucose- exposed cardiomyocytes was confirmed by antibody capture and HPLC-MS (132). Finally, we assessed the effect of ad- vanced glycation end products on angiotensin expression in renal NRK-52E cells (9). Basal cellular content was quantified

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org




by direct RIAs for ANG I (85 fmol/mg protein; Peninsula), ANG II (150 fmol/mg protein; ALPCO), and ANG-(1–7) (400 fmol/mg protein; custom RIA) (9). Advanced glycation end product exposure significantly reduced ANG-(1–7) and in- creased metabolism of the peptide that was associated with myofibroblast transition but did not impact ANG II or ANG I levels (9). As these cells express an intracellular RAS, nuclear content of ANG II and ANG-(1–7) was quantified at 60 fmol/mg protein consistent with nuclear immunostaining for both peptides (10). In review of the cell studies, angiotensin content in various cell types is 200 fmol/mg protein (Table 1). The high angiotensin levels compared with tissues likely reflect the lower cellular protein to normalize peptide content, as well as the greater density of angiotensin-expressing cells maintained in culture; however, direct comparisons of angiotensins quan- tified by RIA (or ELISA) to HPLC-RIA and LC-MS are lacking, and the true cellular content of ANG II or ANG-(1–7) in these cell models is not known. A second issue with cell studies is the presence of circulating RAS components in fetal bovine serum (10). Cells can be maintained in low or serum- free conditions for short periods, but internalized angiotensino- gen or renin may persist and contribute to the intracellular expression of angiotensin peptides, particularly if nonrenin proteases that can process the precursor (cathepsins, tonin) are also expressed. Furthermore, bovine angiotensinogen contains an Ile 5 substitution for Val 5 in the NH 2 -terminal portion of the protein, and RIAs will not distinguish these angiotensin iso- forms unless samples are initially fractionated by HPLC or characterized by LC-MS (130). ANG II also undergoes inter- nalization through both AT 1 R-dependent and -independent pathways that may further contribute to the cellular content of the peptide (40, 92, 140, 150). Indeed, the interaction between the circulating RAS components and the cellular or tissue system is likely a dynamic process in vivo that should be examined to a greater extent in cell studies. Finally, the subcellular compartmentalization of angiotensin peptides and other components is becoming increasingly evident (1, 2, 25, 35, 40, 54, 74, 140, 151). Apart from establishing the func- tional role of these intracellular systems, a greater emphasis should be placed on the quantification of angiotensins in cellular compartments, and particularly the extent that altered peptide content in tissue reflects discrete changes in the sub- cellular systems such as the nucleus and mitochondria.


The current review assessed the biochemical approaches to quantify the multiple components of the RAS, as well as attempt a consensus on expected values of endogenous angio- tensin peptides in the circulation, tissues, and cells. In regard to the peptidase and receptor components of the RAS, an optimal approach should reflect some measure of the activity of these proteins, although it is acknowledged that the receptor expres- sion is an order of magnitude lower than that of other RAS proteins and presents a more difficult challenge for receptor characterization This same issue holds for true for the quanti- fication of angiotensin peptides given their very low abun- dance; optimal approaches should reflect a highly sensitive and specific method coupled with relatively high throughput to evaluate large sample sets. The LC-MS/MS approach appears

to be the ideal choice to quantify angiotensin peptides; how- ever, the required expertise and overall expense of these systems limits their widespread availability to a limited number of laboratories at the current time. Moreover, the application of MS to the determination of angiotensins does not necessarily guarantee an accurate profile or an absolute value in plasma and tissues. Thus RIA or ELISA methods will continue to be the predominant approach to quantify angiotensin peptides and assess alterations in peptide expression. The limitations of these assays, as well as the methods applied for sampling handling, extraction, and approaches for validation, must be considered for the accurate assessment of the peptide hormones of the RAS, as well as to establish that an altered phenotypic or treatment response truly reflects changes in peptide expression. Importantly, validation of these assays for either individual samples or a sample pool by HPLC-RIA should be a require- ment for the analysis of endogenous angiotensin peptides in various compartments, and particularly in studies that assess the cellular expression of angiotensins.


I gratefully acknowledge K. Bridget Brosnihan and Debra I. Diz of the Hypertension and Vascular Research Center for their critical reading and insightful comments pertaining to this review.


This study was supported in part by National Institute of Health Grants HL-56973, HL-51952, HD-084227, HD-047584, and HD-017644 and Amer- ican Heart Association Grants AHA-151521 and AHA-355741. An unre- stricted grant from the Farley-Hudson Foundation (Jacksonville, NC), Groskert Heart Fund, and the Wake Forest Venture Fund is also acknowledged.


No conflicts of interest, financial or otherwise, are declared by the author(s).


M.C.C. drafted, edited, revised, and approved final version of manuscript.


1. Abadir PM, Foster DB, Crow M, Cooke CA, Rucker JJ, Jain A, Smith BJ, Burks TN, Cohn RD, Fedarko NS, Carey RM, O’Rourke B, Walston JD. Identification and characterization of a functional mito- chondrial angiotensin system. Proc Natl Acad Sci USA 108: 14849 – 14854, 2011.

2. Abadir PM, Walston JD, Carey RM. Subcellular characteristics of

functional intracellular renin-angiotensin systems. Peptides 38: 437–445,


3. Ahmad S, Simmons T, Varagic J, Moniwa N, Chappell MC, Ferrario CM. Chymase-dependent generation of angiotensin II from angiotensin- (1–12) in human atrial tissue. PLoS One 6: e28501, 2011.

4. Albiston AL, Fernando RN, Yeatman HR, Burns P, Ng L, Daswani D, Diwakarla S, Pham V, Chai SY. Gene knockout of insulin-regulated

aminopeptidase: loss of the specific binding site for angiotensin IV and age-related deficit in spatial memory. Neurobiol Learn Mem 93: 19 –30,


5. Alge JL, Karakala N, Neely BA, Janech MG, Tumlin JA, Chawla LS, Shaw AD, Arthur JM. Association of elevated urinary concentration of renin-angiotensin system components and severe AKI. Clin J Am Soc Nephrol 8: 2043–2052, 2013.

6. Alghamri MS, Morris M, Meszaros JG, Elased KM, Grobe N. Novel

role of aminopeptidase-A in angiotensin-(1–7) metabolism post myocar- dial infarction. Am J Physiol Heart Circ Physiol 306: H1032–H1040,


7. Ali Q, Wu Y, Nag S, Hussain T. Estimation of angiotensin peptides in biological samples by LC/MS method. Anal Methods 6: 215–222, 2014.

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org





8. Ali Q, Wu Y, Hussain T. Chronic AT 2 receptor activation increases

renal ACE2 activity, attenuates AT 1 receptor function and blood pressure in obese Zucker rats. Kidney Int 84: 931–939, 2013. 9. Alzayadneh EM, Chappell MC. Angiotensin-(1–7) abolishes AGE- induced cellular hypertrophy and myofibroblast transformation via inhi- bition of ERK1/2. Cell Signal 26: 3027–3035, 2014.

10. Alzayadneh EM, Chappell MC. Nuclear expression of renin-angioten- sin system components in NRK-52E renal epithelial cells. J Renin Angiotensin Aldosterone Syst. 2014 Jun 24. pii: 1470320313515039.

[Epub ahead of print].

11. Anderson NL, Anderson NG. The human proteonome. Mol Cell Pro- teonomics 1: 845–867, 2002.

12. Bader M, Alenina N, Andrade-Navarro MA, Santos RA. MAS and its related G protein-coupled receptors, Mrgprs. Pharmacol Rev 66: 1080 – 1105, 2014.

13. Baker M. Reproducibility crisis: blame it on the antibodies. Nature 521:

274 –276, 2015.

14. Balcells E, Meng QC, Hageman GR, Palmer RW, Durand JN, Dell’Italia LJ. Angiotensin II formation in dog heart is mediated by different pathways in vivo and in vitro. Am J Physiol 40: H417–H421,


15. Bernstein KE, Ong FS, Blackwell WL, Shah KH, Giani JF, Gonza- lez-Villalobos RA, Shen XZ, Fuchs S, Touyz RM. A modern under- standing of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev 65: 1–46, 2013.

16. Bertoncello N, Moreria RP, Arita DY, Aragao DS, Watanabe IKM, Dantas PS, Santos R, Mattar-Rosa R, Yokota R, Cunha TS, Casarini DE. Diabetic nephropathy induced by Ace gene dosage is associated with

high renal levels of angiotensin-(1–7) and bradykinin. J Diabetes Res 67:

1–13, 2015.

17. Bkaily G, Nader M, Avedanian L, Choufani S, Jacques D, D’Orleans-Juste P, Gobeil F, Chemtob S, Al-Khoury J. G-protein- coupled receptors, channels, and Na -H exchanger in nuclear mem- branes of heart, hepatic, vascular endothelial, and smooth muscle cells. Can J Physiol Pharmacol 84: 431–441, 2006.

18. Bodineau L, Frugiere A, Marc Y, Inguimbert N, Fassot C, Balavoine F, Roques B, Llorens-Cortes C. Orally active aminopeptidase A inhib- itors reduce blood pressure: a new strategy for treating hypertension. Hypertension 51: 1318 –1325, 2008.

19. Burger D, Reudelhuber TL, Mahajan A, Chibale K, Sturrock ED, Touyz RM. Effects of a domain-selective ACE inhibitor in a mouse model of chronic angiotensin II-dependent hypertension. Clin Sci (Lond) 127: 57–63, 2014.

20. Camenzind AG, van der Gugten JG, Popp R, Holmes DT, Borchers CH. Development and evaluation of an immuno-MALDI (iMALDI) assay for angiotensin I and the diagnosis of secondary hypertension. Clin Proteomics 10: 20, 2013.

21. Campbell DJ. Angiotensin II generation in vivo: does it involve en- zymes other than renin and angiotensin-converting enzyme? J Renin Angiotensin Aldosterone Syst 13: 314 –316, 2012.

22. Campbell DJ, Duncan AM, Kladis A, Harrap SB. Angiotensin pep- tides in spontaneously hypertensive and normotensive donryu rats. Hy- pertension 25: 928 –934, 1995.

23. Campbell DJ, Kladis A, Duncan AM. Nephrectomy, converting en- zyme inhibition and angiotensin peptides. Hypertension 22: 513–522,


24. Campbell DJ, Alexiou T, Xiao HD, Fuchs S, McKinley MJ, Corvol P, Bernstein KE. Effect of reduced ACE gene expression and ACE inhi- bition on angiotensin and bradykinin peptide levels in mice. Hyperten- sion 43: 854 –859, 2004.

25. Carey RM. Functional intracellular renin-angiotensin systems: potential

for pathophysiology of disease. Am J Physiol Regul Integr Comp Physiol 302: R479 –R481, 2012.

26. Castro-Moreno P, Pardo JP, Henandez-Munoz R, Lopez-Guerrero JJ, Valle-Mondragon LD, Pastelin-Hernandez G, Ibarra-Barajas M, Vilalobos-Molina R. Captopril avoids hypertension, the increase in plasma angiotensin II but increases angiotensin 1–7 and angiotensin II-induced perfusion pressure in isolated kidney in SHR. Auton Autacoid Pharmacol 32: 61–69, 2012.

27. Caughey GH, Raymond WW, Wolters PJ. Angiotensin II generation by mast cell alpha- and beta-chymases. Biochim Biophys Acta 1480:

245–257, 2000.

28. Caughey GH. Mast cell proteases as protective and inflammatory me- diators. Adv Exp Med Biol 716: 212–234, 2011.

29. Chappell MC. Emerging evidence for a functional angiotensin-convert- ing enzyme 2-angiotensin-(1–7) mas receptor axis; more than regulation of blood pressure? Hypertension 50: 596 –599, 2007.

30. Chappell MC, Brosnihan KB, Diz DI, Ferrario CM. Identification of angiotensin-(1–7) in rat brain: evidence for differential processing of angiotensin peptides. J Biol Chem 264: 16518 –16523, 1989.

31. Chappell MC, Gomez MN, Pirro NT, Ferrario CM. Release of angiotensin-(1–7) from the rat hindlimb: influence of angiotensin-con- verting enzyme inhibition. Hypertension 35: 348 –352, 2000.

32. Chappell MC, Tallant EA, Brosnihan KB, Ferrario CM. Conversion of angiotensin I to angiotensin-(1–7) by thimet oligopeptidase (EC 3.42415) in vascular smooth muscle cells. J Vasc Med Biol 5: 129 –137,


33. Coelho MS, Lpes KL, de Aquino Frietas R, de Oliveira-Sales EB, Bergasmaschi CT, Campos RB, Casarinin DE, Camona AK, da Silva Arauo M., Heimann JC, Dolnikoff MS. High sucrose intake in rats is associated with increased ACE2 and angiotensin-(1–7) levels in adipose tissue. Regul Pept 162: 61–67, 2010.

34. Cohen JA, Lindsey SH, Pirro NT, Brosnihan KB, Gallagher PE, Chappell MC. Influence of estrogen depletion and salt loading on renal angiotensinogen expression in the mRen(2). Lewis strain. Am J Physiol Renal Physiol 299: F35–F42, 2010.

35. Cook JL, Re RN. Lessons from in vitro studies and a related intracellular angiotensin II transgenic mouse model. Am J Physiol Regul Integr Comp Physiol 302: R482–R493, 2012.

36. Dell’Italia LJ, Meng QC, Balcells E, Wei CC, Palmer R, Hageman GR, Durand J, Hankes GH, Oparil S. Compartmentalization of angio- tensin II generation in the dog heart. Evidence for independent mecha-

nisms in intravascular and interstitial spaces. J Clin Invest 100: 253–258,


37. DeSilva PE, Husain A, Smeby RR, Khairallah PA. Measurements of immunoreactive angiotensin peptides in rat tissues: some pitfalls in angiotensin II analysis. Anal Biochem 174: 80 –87, 1988.

38. Durvasula RV, Petermann AT, Hiromura K, Blonski M, Pippin J, Mundel P, Pichler R, Griffin S, Couser WG, Shankland SJ. Activa- tion of a local tissue angiotensin system in podocytes by mechanical strain. Kidney Int 65: 30 –39, 2004.

39. Elased KM, Cool DR, Morris M. Novel mass spectrometric methods for evaluation of plasma angiotensin converting enzyme 1 and renin activity. Hypertension 46: 953–959, 2005.

40. Ellis B, Li XC, Miguel-Qin E, Gu V, Zhuo JL. Evidence for a

functional intracellular angiotensin system in the proximal tubule of the kidney. Am J Physiol Regul Integr Comp Physiol 302: R494 –R509,


41. Epelman S, Shrestha K, Troughton RW, Francis GS, Sen S, Klein AL, Tang WH. Soluble angiotensin-converting enzyme 2 in human heart failure: relation with myocardial function and clinical outcomes. J Card Fail 15: 565–571, 2009.

42. Fernandes T, Hashimoto NY, Magalhaes FC, Fernandes FB, Casa- rini DE, Carmona AK, Krieger JE, Phillips MI, Oliveira EM. Aerobic exercise training-induced left ventricular hypertrophy involves regulatory MicroRNAs, decreased angiotensin-converting enzyme-an- giotensin ii, and synergistic regulation of angiotensin-converting enzyme 2-angiotensin (1–7). Hypertension 58: 182–189, 2011.

43. Ferrario CM. Angiotensin-converting enzyme 2 and angiotensin-(1–7):

an evolving story in cardiovascular regulation. Hypertension 45: 313– 320, 2006.

44. Ferrario CM, Jessup JA, Gallagher PE, Averill DB, Brosnihan KB, Tallant EA, Smith RD, Chappell MC. Effects of renin angiotensin system blockade on renal angiotensin-(1–7) forming enzymes and recep- tors. Kidney Int 68: 2189 –2196, 2005.

45. Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosni- han KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M. Characterization of angiotensin-(1–7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 11: 137–146, 1998.

46. Ferrario CM, Strawn WB. Role of the renin-angiotensin-aldosterone

system and proinflammatory mediators in cardiovascular disease. Am J Cardiol 98: 121–128, 2006.

47. Ferreira AJ, Murça TM, Fraga-Silva RA, Castro CH, Raizada MK, Santos RA. New cardiovascular and pulmonary therapeutic strategies based on the Angiotensin-converting enzyme 2/angiotensin-(1–7)/mas receptor axis. Int J Hypertens 2012: 147825, 2012.

48. Franco MC, Akamine EH, Di Marco GS, Casarini DE, Fortes ZB, Tostes RC, Carvalho MH, Nigro D. NADPH oxidase and enhanced

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org




superoxide generation in intrauterine undernourished rats: involvement of the renin-angiotensin system. Cardiovasc Res 59: 767–775, 2003.

49. Garabelli PJ, Modrall JG, Penninger JM, Ferrario CM, Chappell MC. Distinct roles for angiotensin converting enzyme 2 and carboxy- peptidase A in the processing of angiotensins in the murine heart. Exp Physiol 95: 613–621, 2008.

50. Gilliam-Davis S, Payne VS, Kasper SO, Tommasi EN, Robbins ME, Diz DI. Long-term AT 1 receptor blockade improves metabolic function and provides renoprotection in Fischer-344 rats. Am J Physiol Heart Circ Physiol 293: H1327–H1333, 2007.

51. Gomes-Santos IL, Fernandes T, Couto GK, Ferreira-Filho JC, Sa- lemi VM, Fernandes FB, Casarini DE, Brum PC, Rossoni LV, de Oliveira EM, Negrao CE. Effects of exercise training on circulating and skeletal muscle renin-angiotensin system in chronic heart failure rats. PLoS One 9: e98012, 2014.

52. Gonzalez AA, Prieto MC. Roles of collecting duct renin and prorenin receptor in hypertension. Ther Adv Cardiovasc Dis 9: 191–200, 2015.

53. Grobe N, Elased KM, Cool DR, Morris M. Mass spectrometry for the molecular imaging of angiotensin metabolism in kidney. Am J Physiol Endocrinol Metab 302: E1016 –E1024, 2012.

54. Gwathmey TM, Alzayadneh EM, Pendergrass KD, Chappell MC. Novel roles of nuclear angiotensin receptors and signaling mechanisms. Am J Physiol Regul Integr Comp Physiol 302: R518 –R530, 2012.

55. Gwathmey TM, Pendergrass KD, Reid SD, Rose JC, Diz DI, Chap- pell MC. Angiotensin-(1–7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension 55: 166 –171, 2010.

56. Gwathmey TM, Shaltout HA, Pendergrass KD, Pirro NT, Figueroa JP, Rose JC, Diz DI, Chappell MC. Nuclear angiotensin II type 2 (AT 2 )

receptors are functionally linked to nitric oxide production. Am J Physiol Renal Physiol 296: F1484 –F1493, 2009.

57. Gwathmey TM, Shaltout HA, Rose JC, Diz DI, Chappell MC. Glucocorticoid-induced fetal programming alters the functional comple- ment of angiotensin receptor subtypes within the kidney. Hypertension 57: 620 –626, 2011.

58. Gwathmey TM, Westwood BM, Pirro NT, Tang L, Rose JC, Diz DI, Chappell MC. Nuclear angiotensin-(1–7) receptor is functionally cou- pled to the formation of nitric oxide. Am J Physiol Renal Physiol 299:

F983–F990, 2010.

59. Hafko R, Villapol S, Nostramo R, Symes A, Sabban EL, Inagami T, Saavedra JM. Commercially available angiotensin II At(2) receptor antibodies are nonspecific. PLoS One 8: e69234, 2013.

60. Haschke M, Schuster M, Poglitsch M, Loibner H, Salzberg M, Bruggisser M, Penninger J, Krahenbuhl S. Pharmacokinetics and pharmacodynamics of recombinant human angiotensin-converting en- zyme 2 in healthy human subjects. Clin Pharmacokinet 52: 783–792,


61. Herrera M, Sparks MA, Alfonso-Pecchio AR, Harrison-Bernard LM, Coffman TM. Lack of specificity of commercial antibodies leads to misidentification of angiotensin type 1 receptor protein. Hypertension 61:

253–258, 2013.

62. Hildebrand D, Merkel P, Eggers LF, Schluter H. Proteolytic process- ing of angiotensin-I in human blood plasma. PLoS One 8: e64027, 2013.

63. Hilgers KF, Bingener E, Stumpf C, Muller DM, Schmieder RE, Veelken R. Angiotensinases restrict locally generated angiotensin II to the blood vessel wall. Hypertension 31: 368 –372, 1998.

64. Inoue H, Fukui K, Takashi S, Miyake Y. Genetic and molecular properties of the human and rat renin binding protein with reference to the function of the leucine zipper motif. J Biochem 110: 493–500, 1991.

65. Ishigami T, Kino T, Chen L, Minegishi S, Araki N, Umemura M, Abe K, Sasaki R, Yamana H, Umemura S. Identification of bona fide alternative renin transcripts expressed along cortical tubules and potential roles in promoting insulin resistance in vivo without significant plasma renin activity elevation. Hypertension 64: 125–133, 2014.

66. Jankowski V, Tolle M, Santos RA, Gunthner T, Krause E, Beyer- mann M, Welker P, Bader M, Pinheiro SV, Sampaio WO, Lautner R, Kretschmer A, van der Giet M, Zidek W, Jankowski J. Angio- protectin: an angiotensin II-like peptide causing vasodilatory effects. FASEB J 25: 2987–2995, 2011.

67. Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J. Mass-spectrometric identification

of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27: 297–302, 2007.

68. Kemp BA, Bell JF, Rottkamp DM, Howell NL, Shao W, Navar LG, Padia SH, Carey RM. Intrarenal angiotensin III is the predominant agonist for proximal tubule angiotensin type 2 receptors. Hypertension 60: 387–395, 2012.

69. Kobori H, Alper AB Jr, Shenava R, Katsurada A, Saito T, Ohashi N, Urushihara M, Miyata K, Satou R, Hamm LL and Navar LG. Urinary angiotensinogen as a novel biomarker of the intrarenal renin- angiotensin system status in hypertensive patients. Hypertension 53:

344 –350, 2009.

70. Kobori H, Katsurada A, Miyata K, Ohashi N, Satou R, Saito T, Hagiwara Y, Miyashita K, Navar LG. Determination of plasma and urinary angiotensinogen levels in rodents by newly developed ELISA. Am J Physiol Renal Physiol 294: F1257–F1263, 2008.

71. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hyper- tension and kidney disease. Pharmacol Rev 59: 251–287, 2007.

72. Kobori H, Ohashi N, Katsurada A, Miyata K, Satou R, Saito T, Yamamoto T. Urinary angiotensinogen as a potential biomarker of severity of chronic kidney diseases. J Am Soc Hypertens 2: 349 –354,


73. Kohara K, Tabuchi Y, Senanayake P, Brosnihan KB, Ferrario CM.

Reassessment of plasma angiotensins measurement: effects of protease inhibitors and sample handling procedures. Peptides 12: 1135–1141,


74. Kumar R, Thomas CM, Yong QC, Chen W, Baker KM. The intra- crine renin-angiotensin system. Clin Sci (Lond) 123: 273–284, 2012.

75. Lautner RQ, Villela DC, Fraga-Silva RA, Silva N, Verano-Braga T, Costa-Fraga F, Jankowski J, Jankowski V, Sousa F, Alzamora A, Soares E, Barbosa C, Kjeldsen F, Oliveira A, Braga J, Savergnini S, Maia G, Peluso AB, Passos-Silva D, Ferreira A, Alves F, Martins A, Raizada M, Paula R, Motta-Santos D, Klempin F, Pimenta A, Alenina N, Sinisterra R, Bader M, Campagnole-Santos MJ, Santos RA. Discovery and characterization of alamandine: a novel component of the renin-angiotensin system. Circ Res 112: 1104 –1111, 2013.

76. Lavoie JL, Liu X, Bianco RA, Beltz TG, Johnson AK, Sigmund CD. Evidence supporting a functional role for intracellular renin in the brain. Hypertension 47: 461–466, 2006.

77. Lavrentyev EN, Estes AM, Malik KU. Mechanism of high glucose induced angiotensin II production in rat vascular smooth muscle cells. Circ Res 101: 455–464, 2007.

78. Lawrence AC, Evin G, Kladis A, Campbell DJ. An alternative strategy for the radioimmunoassay of angiotensin peptides using amino-terminal- directed antisera: measurement of eight angiotensin peptides in human plasma. J Hypertens 8: 715–724, 1990.

79. Lew RA. HPLC in the analysis of peptide metabolism. Methods Mol Biol 251: 275–290, 2004.

80. Lew RA, Mustafa T, Ye S, McDowall SG, Chai SY, Albiston AL. Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 86: 344 –350, 2003.

81. Lew RA, Tochon-Danguy N, Hamilton CA, Stewart KM, Aguilar MI, Smith AI. Quenched fluorescent substrate-based peptidase assays. Methods Mol Biol 298: 143–150, 2005.

82. Liu L, Gonzalez AA, McCormack M, Seth DM, Kobori H, Navar LG, Prieto MC. Increased renin excretion is associated with augmented urinary angiotensin II levels in chronic angiotensin II-infused hyperten- sive rats. Am J Physiol Renal Physiol 301: F1195–F1201, 2011.

83. Lortie M, Bark S, Blantz R, Hook V. Detecting low-abundance vasoactive peptides in plasma: progress toward absolute quantitation using nano liquid chromatography-mass spectrometry. Anal Biochem 394: 164 –170, 2009.

84. Lumbers ER, Skinner SL. Origin of renin activity in human urine. Circ Res 24:689 – 697 1969.

85. Mazzolai L, Pedrazzini T, Nicoud F, Gabbiani G, Brunner HR, Nussberger J. Increased cardiac angiotensin II levels induce right and left ventricular hypertrophy in normotensive mice. Hypertension 35:

985–991, 2000.

86. Miners JS, Verbeek MM, Rikkert MO, Kehoe PG, Love S. Immuno- capture-based fluorometric assay for the measurement of neprilysin- specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods 167: 229 –236, 2008.

87. Mizuno K, Tani M, Niimura S, Hashimoto S, Satoh A, Shimamoto K, Inagami T, Fukuchi S. Direct evidence for local generation and release

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org





of angiotensin II in human vascular tissue. Biochem Biophys Res Com- mun 165: 457–463, 1989.

88. Modrall JG, Sadjadi J, Brosnihan KB, Gallagher PE, Ya CH, Kramer GL, Bernstein KE, Chappell MC. Depletion of tissue ace

differentially influences the intrarenal and urinary expression of angio- tensins. Hypertension 43: 4849 –4853, 2003.

89. Nagata S, Hatakeyama K, Asami M, Tokashiki M, Hibino H, Nishiu- chi Y, Kuwasako K, Kato J, Asada Y, Kitamura K. Big angiotensin- 25: a novel glycosylated angiotensin-related peptide isolated from human urine. Biochem Biophys Res Commun 441: 757–762, 2013.

90. Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K. Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Commun 350:

1026 –1031, 2006.

91. Navar LG, Imig JD, Zou L, Wang CT. Intrarenal production of angiotensin II. Semin Nephrol 17: 412–422, 1997.

92. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA. Intratu- bular renin-angiotensin system in hypertension. Hypertension 57: 355– 362, 2011.

93. Navar LG, Prieto MC, Satou R, Kobori H. Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. Curr Opin Pharmacol 11: 180 –186, 2011.

94. Nguyen G. Renin/prorenin receptors. Kidney Int 69: 1503–1506, 2006.

95. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid angiotensin I and angiotensin II concentrations during local angiotensin-converting enzyme inhibition. J Am Soc Nephrol 13: 2207–2212, 2002.

96. Nishiyama A, Seth DM, Navar LG. Renal interstitial fluid concentra- tions of angiotensins I and II in anesthetized rats. Hypertension 39:

129 –134, 2002.

97. Nussberger J, Brunner DB, Nyfeler JA, Linder L, Brunner HR. Measurement of immunoreactive angiotensin-(1–7) heptapeptide in hu- man blood. Clin Chem 47: 726 –729, 2001.

98. Nussberger J, Brunner DB, Waeber B, Brunner HR. True versus immunoreactive angiotensin II in human plasma. Hypertension 7, Suppl I: I-1–I-7, 1985 .

99. Nussberger J, Buhler K, Waeber B, Brunner HR. Identification and quantitation of angiotensins. J Cardiovasc Pharmacol 8, Suppl 10:

S23–S28, 1986.

100. Nussberger J, Wuerzner G, Jensen C, Brunner HR. Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril. Hypertension 39: E1–E8, 2002.

101. Ocaranza MP, Michea L, Chiong M, Lagos CF, Lavandero S, Jalil JE. Recent insights and therapeutic perspectives of angiotensin-(1–9) in the cardiovascular system. Clin Sci (Lond) 127: 549 –557, 2014.

102. Olkowicz M, Radulska A, Suraj J, Kij A, Walczak M, Chlopicki S,

Smolenski RT. Development of a sensitive, accurate and robust liquid chromatography/mass spectrometric method for profiling of angiotensin peptides in plasma and its application for atherosclerotic mice. J Chro- matogr A 1393: 37–46, 2015.

103. Padia SH, Kemp BA, Howell NL, Gildea JJ, Keller SR, Carey RM. Intrarenal angiotensin III infusion induces natriuresis and angiotensin type 2 receptor translocation in Wistar-Kyoto but not in spontaneously hypertensive rats. Hypertension 53: 338 –343, 2009.

104. Pendergrass KD, Averill DB, Ferrario CM, Diz DI, Chappell MC. Differential expression of nuclear AT 1 receptors and angiotensin II within the kidney of the male congenic mRen2. Lewis rat. Am J Physiol Renal Physiol 290: F1497–F1506, 2006.

105. Pendergrass KD, Gwathmey TM, Michalek RD, Grayson JM, Chap- pell MC. The angiotensin II-AT1 receptor stimulates reactive oxygen species within the cell nucleus. Biochem Biophys Res Commun 384:

149 –154, 2009.

106. Peters J, Clausmeyer S. Intracellular sorting of renin: cell type specific differences and their consequences. J Mol Cell Cardiol 34: 1561–1568,


107. Peters J, Wanka H, Peters B, Hoffmann S. A renin transcript lacking exon 1 encodes for a non-secretory intracellular renin that increases aldosterone production in transgenic rats. J Cell Mol Med 12: 1229 – 1237, 2008.

108. Poglitsch M, Domenig O, Schwager C, Stranner S, Peball B, Janzek E, Wagner B, Jungwirth H, Loibner H, Schuster M. Recombinant expression and characterization of human and murine ACE2: Species- specific activation of the alternative renin-angiotensin-System. Int J Hypertens 2012: 428950, 2012.

109. Reaux-Le GA, Iturrioz X, Fassot C, Claperon C, Roques BP, Llo- rens-Cortes C. Role of angiotensin III in hypertension. Curr Hypertens Rep 7: 128 –134, 2005.

110. Ribeiro AA, Palomino Z, Lima MP, Souza LE, Ferreira DS, Pes- quero JB, Irigoyen MC, Pesquero JL, Casarini DE. Characterization

of the renal renin-angiotensin system in transgenic mice that express rat

tonin. J Renin Angiotensin Aldosterone Syst. 2015 Jul 27. pii:

1470320315595572. [Epub ahead of print].

111. Rice GI, Jones AL, Grant PJ, Carter AM, Turner AJ, Hooper NM. Circulating activities of angiotensin-converting enzyme, its homolog, angiotensin-converting enzyme 2, and neprilysin in a family study. Hypertension 48: 914 –920, 2006.

112. Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383: 45–51,


113. Roksnoer LC, Verdonk K, van den Meiracker AH, Hoorn EJ, Zietse R, Danser AH. Urinary markers of intrarenal renin-angiotensin system activity in vivo. Curr Hypertens Rep 15: 81–88, 2013.

114. Ronchi FA, Irigoyen MC, Casarini DE. Association of somatic and N-domain angiotensin-converting enzymes from Wistar rat tissue with renal dysfunction in diabetes mellitus. J Renin Angiotensin Aldosterone Syst 8: 34 –41, 2007.

115. Rubio-Ruiz ME, Del Valle-Mondragon L, Castregjon-Tellez V, Carreon-Torees E, Diaz-Diaz E, Guarner-Lans V. Angiotensin II and 1–7 during aging in metabolic syndrome rats Expression of AT1 and AT2 and Mas receptors in abdominal white adipose tissue. Peptides 57:

101–108, 2014.

116. Rykl J, Thiemann J, Kurzawski S, Pohl T, Gobom J, Zidek W, Schluter H. Renal cathepsin G and angiotensin II generation. J Hyper- tens 24: 1797–1807, 2006.

117. Santos CF, Caprio MA, Oliveira EB, Salgado MC, Schippers DN, Munzenmaier DH, Greene AS. Functional role, cellular source, and tissue distribution of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol 285: H775–H783, 2003.

118. Santos CF, Greene AS, Salgado MC, Oliveira EB. Conversion of renin substrate tetradecapeptide to angiotensin II by rat MAB elastase-2. Can J Physiol Pharmacol 82: 1000 –1005, 2004.

119. Santos RA. Angiotensin-(1–7). Hypertension 63: 1138 –114, 2014.

120. Santos RA, Ferreira AJ, Verano-Braga T, Bader M. Angiotensin- converting enzyme 2, angiotensin-(1–7) and Mas: new players of the renin-angiotensin system. J Endocrinol 216: R1–R17, 2013.

121. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Bul I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss H-P, Speth R, Walther T. Angiotensin-(1–7) is an endogenous ligand for the

G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100: 8258 –

8263, 2003.

122. Santos RAS, Krieger EM, Greene LJ. An improved fluorometric assay

of rat serum and plasma converting enzyme. Hypertension 7: 244 –252,


123. Schechter NM, Irani AA, Sprows JL, Abernethy J, Winstroub BU, Schwartz LB. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell. J Immunol 145: 2652–2661, 1990.

124. Schuijt MP, van Kats JP, de ZS, Duncker DJ, Verdouw PD, Schalekamp MA, Danser AH. Cardiac interstitial fluid levels of angio- tensin I and II in the pig. J Hypertens 17: 1885–1891, 1999.

125. Schulz A, Jankowski J, Zidek W, Jankowski V. Absolute quantifica- tion of endogenous angiotensin II levels in human plasma using ESI- LC-MS/MS. Clin Proteomics 11: 37, 2014.

126. Semaan W, Desbiens L, Houde M, Labonte J, Gagnon H, Yamamoto D, Takai S, Laidlaw T, Bkaily G, Schwertani A, Pejler G, Levesque C, Desjardins R, Day R, D’Orleans-Juste P. Chymase inhibitor- sensitive synthesis of endothelin-1 (1–31) by recombinant mouse mast cell protease 4 and human chymase. Biochem Pharmacol 94: 91–100,


127. Senanayake PD, Moriguchi A, Kumagai H, Ganten D, Ferrario CM,

Brosnihan KB. Increased expression of angiotensin peptides in the brain

of transgenic hypertensive rats. Peptides 15: 919 –926, 1994.

128. Senanayake PS, Smeby RR, Martins AS, Moriguchi A, Kumagai H, Ganten D, Brosnihan KB. Adrenal, kidney, and heart angiotensins in female murine Ren-2 transfected hypertensive rats. Peptides 19: 1685– 1694, 1998.

AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org




129. Shaltout HA, Westwood B, Averill DB, Ferrario CM, Figueroa J, Diz DI, Rose JC, Chappell MC. Angiotensin metabolism in renal proximal tubules, urine and serum of sheep: Evidence for ACE2-dependent pro-

cessing of Angiotensin II. Am J Physiol Renal Physiol 292: F82–F91,


130. Shao W, Seth DM, Navar LG. Augmentation of endogenous intrarenal angiotensin II levels in Val 5 -Ang II-infused rats. Am J Physiol Renal Physiol 296: F1067–F1071, 2009.

131. Shi Y, Lo CS, Padda R, Abdo S, Chenier I, Filep JG, Ingelfinger JR, Zhang SL, Chan JS. Angiotensin-(1–7) prevents systemic hypertension, attenuates oxidative stress and tubulointerstitial fibrosis, and normalizes renal angiotensin-converting enzyme 2 and Mas receptor expression in diabetic mice. Clin Sci (Lond) 128: 649 –663, 2015.

132. Singh VP, Le B, Bhat VB, Baker KM, Kumar R. High-glucose- induced regulation of intracellular ANG II synthesis and nuclear redis- tribution in cardiac myocytes. Am J Physiol Heart Circ Physiol 293:

H939 –H948, 2007.

133. Suski M, Gebska A, Olszanecki R, Stachowicz A, Uracz D, Madej J, Korbut R. Influence of atorvastatin on angiotensin I metabolism in resting and TNF-alpha -activated rat vascular smooth muscle cells. J Renin Angiotensin Aldosterone Syst 15: 378 –383, 2014.

134. Te RL, van Esch JH, Roks AJ, van den Meiracker AH, Danser AH. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res 116: 960 –975, 2015.

135. Tenorio-Lopez FA, Zarco-Olvera G, Sanchez-Mendoza A, Rosas- Peralta M, Pastelin-Hernandez G, Del Valle-Mondragon L. Simulta- neous determination of angiotensins II and 1–7 by capillary zone elec- trophoresis in plasma and urine from hypertensive rats. Talanta 80:

1702–1712, 2010.

136. Tikellis C, Bialkowski K, Pete J, Sheehy K, Su Q, Johnston C, Cooper M, Thomas M. ACE2 deficiency modifies renoprotection af- forded by ACE inhibition in experimental diabetes. Diabetes 57: 1018 – 1025, 2008.

137. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275: 33238 –33243, 2000.

138. Urata H, Kinoshita A, Misono KS, Bumpus FM, Husain A. Identifi- cation of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart. J Biol Chem 265: 22348 –22357, 1990.

139. Van den Heuvel M, Batenburg WW, Jainandunsing S, Garrelds IM, van Gool JM, Feelders RA, van den Meiracker AH, Danser AH. Urinary renin, but not angiotensinogen or aldosterone, reflects the renal renin-angiotensin-aldosterone system activity and the efficacy of renin- angiotensin-aldosterone system blockade in the kidney. J Hypertens 29:

2147–2155, 2011.

140. Van Kats JP, Schalekamp MA, Verdouw PD, Duncker DJ, Danser AH. Intrarenal angiotensin II: interstitial and cellular levels and site of production. Kidney Int 60: 2311–2317, 2001.

141. Vidotti DB, Casarini DE, Cristovam PC, Leite CA, Schor N, Boim

MA. High glucose concentration stimulates intracellular renin activity and angiotensin II generation in rat mesangial cells. Am J Physiol Renal Physiol 286: F1039 –F1045, 2004.

142. Wanka H, Kessler N, Ellmer J, Endlich N, Peters BS, Clausmeyer S, Peters J. Cytosolic renin is targeted to mitochondria and induces apo- ptosis in H9c2 rat cardiomyoblasts. J Cell Mol Med 13: 2926 –2937,


143. Westwood BM, Chappell MC. Divergent pathways for the angiotensin- (1–12) metabolism in the rat circulation and kidney. Peptides 35: 190 – 195, 2012.

144. Wilson BA, Cruz-Diaz N, Marshall AC, Pirro NT, Su Y, Gwathmey TM, Rose JC, Chappell MC. An angiotensin-(1–7) peptidase in the kidney cortex, proximal tubules, and human HK-2 epithelial cells that is distinct from insulin-degrading enzyme. Am J Physiol Renal Physiol 308:

F594 –F601, 2015.

145. Wilson BA, Marshall AC, Alzayadneh EM, Chappell MC. The ins and outs of angiotensin processing within the kidney. Am J Physiol Regul Integr Comp Physiol 307: R487–R489, 2014.

146. Wintroub BU, Schechter NB, Lazarus GS, Kaempfer CE, Schwartz LB. Angiotensin I conversion by human rat chymotryptic proteinases. J Invest Dermatol 83: 336 –339, 1984.

147. Wysocki J, Ye M, Batlle D. Plasma and kidney angiotensin peptides:

importance of the aminopeptidase A/angiotensin III axis. Am J Hypertens 28: 1418 –1426, 2015.

148. Yamaleyeva LM, Gilliam-Davis S, Almeida I, Brosnihan KB, Lindsey SH, Chappell MC. Differential regulation of circulating and renal ACE2 and ACE in hypertensive mRen2. Lewis rats with early-onset diabetes. Am J Physiol Renal Physiol 302: F1374 –F1384,


149. Yang R, Smolders I, Vanderheyden P, Demaegdt H, Van Eeckhaut A, Vauquelin G, Lukazuk A, Tourwe D, Chai SY, Albiston AL, Nahmias C, Walther T, Dupont AG. Pressor and renal hemodynamic effects of the novel angiotensin A peptide are AT 1a -receptor dependent.

Hypertension 57: 956 –964, 2011.

150. Yang R, Walther T, Gembardt F, Smolders I, Vanderheyden P, Albiston AL, Chai SY, Dupont AG. Renal vasoconstrictor and pressor responses to angiotensin IV in mice are AT 1a -receptor mediated. J Hypertens 28: 487–494, 2010.

151. Zhuo JL, Li XC. New insights and perspectives on intrarenal renin-

angiotensin system: focus on intracrine/intracellular angiotensin II. Pep- tides 32: 1551–1565, 2011.

152. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1–7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin- converting enzyme homologue ACE2. Circulation 108: 1707–1712,


AJP-Heart Circ Physiol doi:10.1152/ajpheart.00618.2015 www.ajpheart.org